| BEN |
Report |
Adjusted Diluted EPS |
BEAT |
pred ~$0.72 vs. cons $0.66 |
MEDIUM |
| BEN |
Report |
Total Revenue (Investment Mgmt Fees) |
BEAT |
pred ~$1.81B vs. cons $1.76B |
MEDIUM |
| BEN |
Report |
Adjusted Operating Margin |
BEAT |
pred ~27.8% vs. cons ~27.0% |
MEDIUM |
| BEN |
Guide |
Q4 FY2026 Adjusted Operating Margin Guide |
BETTER |
guide ~28.5% vs. cons ~27.8% (Q4 FY2026) |
MEDIUM |
| BEN |
Guide |
FY2027 Margin Target (30%+) |
UNCHANGED |
guide ~30%+ vs. cons ~29.5% (FY2027) |
LOW |
| BEN |
Guide |
Effective Fee Rate (bps) |
UNCHANGED |
guide ~37.5bps vs. cons ~37.3bps (Q3 FY2026 realized/Q4 guide) |
MEDIUM |
| BEN |
Guide |
Alternatives Fundraising Full-Year Target |
BETTER |
guide >$30B vs. cons ~$28B (FY2026) |
LOW |
| BEN |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| BEN |
Return |
5-day cumulative residual |
+0.4% (FADE) |
Beat is largely pre-signaled via monthly AUM disclosures (already public through June), so the incremental surprise is mostly in margin/expense execution rather than top-line, capping the initial pop. Elevated retention/compensation expense (new $60M equity awards, carry incentives, higher G&A tied to fundraising) and the persistent Western Asset outflow drag create implicit downward pressure on out-quarter (Q4/FY27) estimates even if Q3 beats, since consensus will need to absorb higher run-rate comp/G&A against a 'flat markets' AUM assumption that has already been exceeded. With the stock up 35-40% YTD and near highs, a good-not-great margin/expense readout likely sees the initial gain partially faded over the week as sell-side normalizes forward EPS for higher opex rather than raising numbers 1:1 with the AUM beat. |
LOW |